Yusuke Watanabe
A5030693549- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Atrial Fibrillation Management and Outcomes
- Coronary Interventions and Diagnostics
- Aortic Disease and Treatment Approaches
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Structural Anomalies and Repair
- Venous Thromboembolism Diagnosis and Management
- Aortic aneurysm repair treatments
- Cardiac pacing and defibrillation studies
- Acute Myocardial Infarction Research
- Peripheral Artery Disease Management
- Heart Failure Treatment and Management
- Electrolyte and hormonal disorders
- Cardiac and Coronary Surgery Techniques
- Cerebrovascular and Carotid Artery Diseases
- Acute Ischemic Stroke Management
- Lipoproteins and Cardiovascular Health
- ECG Monitoring and Analysis
- Congenital Heart Disease Studies
- Ultrasound in Clinical Applications
Teikyo University
2016-2025
Teikyo University Hospital
2015-2024
Tokyo Institute of Technology
2022-2024
New Tokyo Hospital
2014-2024
Tokyo Medical University
2022-2023
Keio University
2017-2022
Rigshospitalet
2019
Kitasato University
2019
Hitachi (Japan)
2019
Rabin Medical Center
2016-2018
The semiquantitative Clinical Frailty Scale (CFS) is a simple tool to assess patients' frailty and has been shown correlate with mortality in elderly patients even when evaluated by nongeriatricians. aim of the current study was determine prognostic value CFS who underwent transcatheter aortic valve replacement.We utilized OCEAN (Optimized Catheter Valvular Intervention) Japanese multicenter registry review data 1215 replacement. Patients were categorized into 5 groups based on stages: 1-3,...
encompassing the estimated benefit in proportion to risk (Tables 1,2).
The optimal timing to perform percutaneous coronary interventions (PCI) in transcatheter aortic valve implantation (TAVI) patients remains unknown.
Background— Bicuspid aortic valve (BAV) is regarded as a relative contraindication to transcatheter implantation attributable the risk of uneven expansion bioprosthesis. The purpose this study was evaluate efficacy and safety in patients with BAV. Methods Results— Of 470 included our prospective database (October 2006–January 2012), 229 consecutive undergoing both echocardiography multidetector computed tomography were analyzed. We compared clinical outcomes vs without In series patients,...
The authors sought to investigate the prevalence, risk factors, and mid-term mortality in Asian patients with prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR).Little information is available on PPM TAVR patients.The included 1,558 enrolled OCEAN-TAVI (Optimized transCathEter vAlvular iNtervention) Japanese multicenter registry from October 2013 July 2016 excluding who died following before discharge. was defined as moderate if ≧0.65 but ≦0.85 cm2/m2, or...
Background: The occurrence and clinical impact of untreated subclinical leaflet thrombosis beyond 1 year after transcatheter aortic valve replacement still remain unclear. Methods Results: In a multicenter registry, we analyzed data from 485 patients who underwent 4-dimensional multidetector computed tomography posttranscatheter performed to survey hypoattenuated thickening with reduced motion compatible thrombus at median 3 days, 6 months, year, 2 years, years. Incidence, predictors,...
The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied.We conducted a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban in patients prevalent or incident the indication anticoagulation TAVR. primary efficacy outcome was composite adverse events consisting death from any cause, myocardial infarction, ischemic...
Background Limited data are available about clinical outcomes and residual mitral regurgitation (MR) after transcatheter edge-to-edge repair in the large Asian-Pacific cohort. Methods Results From Optimized Catheter Valvular Intervention (OCEAN-Mitral) registry, a total of 2150 patients (primary cause 34.6%) undergoing were analyzed classified into 3 groups according to MR severity at discharge: 0+/1+, 2+, 3+/4+. The mortality heart failure hospitalization rates 1 year 12.3% 15.0%,...
Renal impairment is associated with poor clinical outcomes in patients cardiovascular diseases. Some studies have revealed the impact of renal on who underwent mitral valve transcatheter edge-to-edge repair (M-TEER). However, limited data are available regarding baseline after M-TEER Asian-Pacific heart failure and severe regurgitation. This study sought to examine effect using a large-scale nationwide registry Japan. A total 2,150 enrolled OCEAN-Mitral (Optimized Catheter Valvular...
Aims: Our aim was to validate patient-specific software integrating baseline anatomy and biomechanical properties of both the aortic root valve for prediction morphology leaflet calcium displacement after TAVI.Methods results: Finite element computer modelling performed in 39 patients treated with a Medtronic CoreValve System (MCS; n=33) or an Edwards SAPIEN XT (ESV; n=6).Quantitative axial frame at inflow (MCS, ESV) nadir, coaptation commissures (MCS) compared between multislice computed...
Objective The persistence of left ventricular (LV) hypertrophy is associated with poor clinical outcomes after transcatheter aortic valve implantation (TAVI) for stenosis. However, the optimal medical therapy TAVI remains unknown. We investigated effect renin−angiotensin system (RAS) blockade on LV and mortality in patients undergoing TAVI. Methods Between October 2013 April 2016, 1215 were prospectively enrolled Optimized CathEter vAlvular iNtervention (OCEAN)-TAVI registry. This cohort was...